Aug 2026· Science Advances· Vol 12· 0 citations· 88 references
Medicine
TL;DR
Findings reveal the unique ability of uAbs to selectively deplete abnormal proteins in vitro and in vivo and open the door to peptide-programmable biologic modulators of other disease-causing proteins.
Abstract
Aberrant activation of Wnt signaling results in unregulated accumulation of cytosolic β-catenin, which subsequently enters the nucleus and promotes transcription of genes that contribute to cellular proliferation and malignancy. Here, we sought to eliminate pathogenic β-catenin from the cytosol using designer ubiquibodies (uAbs), chimeric proteins composed of an E3 ubiquitin ligase and a target-binding domain that redirect intracellular proteins to the proteasome for degradation. To accelerate uAb development, we leveraged a protein language model–driven algorithm called SaLT&PepPr to computationally design “guide” peptides with affinity for β-catenin, which were subsequently fused to the catalytic domain of a human E3 called carboxyl terminus of Hsp70-interacting protein. Expression of the resulting peptide-guided uAbs in colorectal cancer cells led to the identification of several designs that greatly reduced the abnormally stable pool of free β-catenin in the cytosol and nucleus while preserving the normal membrane–associated subpopulation. This selective knockdown of pathogenic β-catenin suppressed Wnt/β-catenin signaling and impaired tumor cell survival and proliferation. Furthermore, one of the best degraders selectively decreased cytosolic but not membrane-associated β-catenin levels in livers of BALB/c mice following delivery as a lipid nanoparticle–encapsulated mRNA. Collectively, these findings reveal the unique ability of uAbs to selectively deplete abnormal proteins in vitro and in vivo and open the door to peptide-programmable biologic modulators of other disease-causing proteins.
Prostate cancer (PC) is one of the most common male cancers. Cancer cells are well known for their capacity to avoid programed cell death (PCD) via a variety of molecular pathways, allowing them to survive oncogenic stress and therapeutic challenges. Although oncogenic splicing factors are frequently dysregulated in tu...
This review systematically integrates advances in STAMBPL1 biology from structural to translational studies, highlighting its promise as a therapeutic target for precision cancer therapy.
Hu Lei, Han-Zhang Xu, Li Yang et al.· Molecular Biology Reports· 0 citations
Non-coding RNAs (ncRNAs) are key regulators of cancer progression and have emerged as promising therapeutic targets. However, current approaches for targeting oncogenic ncRNAs remain limited, and expanding the repertoire of cellular degradation pathways available for selective ncRNA elimination remains a significant...
Wen-Chen Pu, Xin-Yu Ouyang, Han-Hao Peng et al.· Journal of Medicinal Chemist...· 0 citations
Wnt signaling controls cellular development by regulating levels of β-catenin, a dual transcription factor and adhesion protein. The tumor suppressor gene Adenomatous Polyposis coli (APC) is a negative regulator of Wnt signaling that acts by interacting with multiple proteins in the destruction complex to drive β-caten...
Darius M. Johnston, C. Tarver, Ryan D. Leib et al.· bioRxiv· 0 citations
USP42 is identified as a novel oncogenic deubiquitinase in LUAD that promotes tumor progression and immune escape by deubiquitinating and stabilizing PTGS2, and targeting USP42 is a promising strategy against LUAD.
Hai-Nan Ye, Ji Shen, Dan Liu et al.· Journal of Molecular Histolo...· 0 citations